CIS Pharma starts collaboration with the Paul Scherer Institute on antibody-radionuclide conjugates

Bubendorf, Switzerland, Thursday, November 22, 2018 - CIS Pharma has identified the group of Prof. Schibli and Dr. Behe from the Paul Scherer Institute, ETH,  as potential partners for its [...]

Nordic Nanovectors presents promising Phase 1 study results on its antibody-radionuclide conjugate Betalutin

Philadelphia, USA, Thursday, November 1, 2018 - Betalutin is an antibody-radionuclide conjugate, ARC, representing a combination of lilotomab for targeting CD37, a protein that specifically exists on the surface of [...]

Novartis successfully completes acquisition of Endocyte and its new antibody-radionuclide conjugate

Zurich, Switzerland, Thursday, October 18, 2018 - Novartis today announced that it has completed the acquisition of Endocyte, Inc., a US-based biopharmaceutical company focused on developing radioligand and CAR-T therapies [...]

Antibody-drug conjugate market with an estimated CAGR of 19%

New York, USA, Thursday, August 23, 2018 - The advancement in the medical technology is driving the global market for antibody-drug conjugates. Preclinical research, the increasing research activities on antibody [...]

CIS Pharma initiates a new R&D program on antibody-radionuclide conjugates

Bubendorf, Switzerland, Tuesday, July 10, 2018 - Over the course of the past months, CIS Pharma has developed concepts and strategies to conjugate  radioisotopes onto its polymer-drug carriers. First syntheses [...]

CIS Pharma verified compatibility of its polymer-drug carriers to be used in antibody-drug conjugates and antibody-radionuclid conjugates

Bubendorf, Switzerland, Monday, October 16, 2017 - The polymer experts from CIS Pharma successfully accomplished a first proof-of-concept study on the compatibility of their polymer-drug carriers with a conjugation technique [...]

Mylotarg, a new antibody-drug conjugate, ADC, approved by the FDA for treatment of acute myeloid leukemia

Maryland, USA, Friday, September 1, 2017 - The U.S. Food and Drug Administration approved the ADC Mylotarg, gemtuzumab ozogamicin, for the treatment of adults with newly diagnosed acute myeloid leukemia, [...]

Besponsa, a new antibody-drug conjugate, ADC, approved in the EU

London, GB, Thursday, June 29, 2017 - The ADC Besponsa - inotuzumab ozogamicin, Pfizer Inc. - is a cancer medicine used to treat a type of blood cancer which affects [...]

CIS Pharma presenting ADC drug carrier technology at Swiss Biotech Day 2017

Basel, Switzerland, Thursday, May 4, 2017 - CIS Pharma presents its ADC drug carrier technology at Swiss Biotech Day 2017, scheduled for 14:10 during the Emerging Companies Streams. CIS Pharma [...]

CIS Pharma announces the first milestones in its ADC research program are achieved

Bubendorf, Switzerland, Thursday, January 21, 2016 - Proof of concept studies at NBE Therapeutics demonstrated conjugation of CIS Pharma’s Cellophil® Smart Polymer drug carrier to antibodies. Consequently, different linkers [...]